-
A Game-Changing Advance in TB Diagnostics: NEJM Publishes Landmark Validation of the Pluslife MiniDock MTB Test
Groundbreaking research published in The New England Journal of Medicine validated the near-point-of-care molecular test across 7 high-burden tuberculosis countries.
넶139 2026-04-30 -
New Preprint Supports Tongue Swab TB Molecular Testing with Pluslife MiniDock MTB Test
A new multi-country preprint suggests that tongue swab molecular testing using the Pluslife MiniDock MTB Test can provide TB case detection comparable to sputum-based methods, while improving sample accessibility and patient comfort.
넶204 2025-11-14 -
Study Update: MiniDock MTB Performance in Cameroon
A new multi-center study in Cameroon reports that the Pluslife MiniDock MTB Test enables accurate, field-ready molecular TB testing in real-world settings.
넶184 2025-11-10 -
Clinical Evaluation of Pluslife MiniDock MTB Test Published in eBioMedicine
A multi-country study in The Lancet eBioMedicine reports a clinical evaluation of the Pluslife MiniDock MTB Test, with swab-based accuracy meeting near point-of-care targets and low invalid rates.
넶265 2025-11-04 -
World Health Day 2025 | Prioritizing Maternal Health to Reduce Preventable Risks
Healthy starts, brighter charts — protect moms and babies with smart GBS checks.
넶144 2025-04-08 -
Ending TB: Pluslife Accelerates Diagnostic Progress with Innovative Technology
As a pioneer in molecular point-of-care testing, Pluslife is committed to delivering efficient, accurate, affordable, and accessible diagnostic solutions—overcoming the limitations of traditional methods and driving global progress in precise TB detection through technological innovation.
넶195 2025-03-24
